They posted a 9-cent earnings beat off a $3.14 basis, higher-than-expected revenue, up 5.4% year-over-year. They also said their full-year revenue growth would be toward the high end of their previously issued guidance, raised the low end of the earnings per share outlook, and that's why the stock jumped almost 4%. Management adjusted the lower boundary of its full-year adjusted diluted EPS forecast upward to a revised range of $12.62 to $12.72. Full-year revenue growth expectations were similarly refined toward the upper tier of initial guidance. Trading at approximately 14 times forward earnings estimates, the stock continues to be modest for a major medical technology company.